Hers vs IVIM Health: Branded Wegovy vs Compounded GLP-1 Plans
Choosing between Hers and IVIM Health comes down to branded FDA-approved medication versus lower-cost compounded GLP-1s. Quick verdict: Hers emphasizes FDA-approved Wegovy and no compounded medications starting at $149/mo, while IVIM Health offers compounded semaglutide or tirzepatide starting at $75/mo with a free month code and strong third-party ratings.
Head-to-head: core differences between Hers vs IVIM Health
This direct comparison focuses on the most distinctive differences supported by the source: medication type and regulatory status, pricing and membership structure, clinical protocol and outcomes claims, and third-party ratings and verification. Each section contrasts the two providers using source facts only.
1. Medication type and regulatory status
Hers: Offers FDA-approved Wegovy, explicitly stating brand-name semaglutide that is not a compounded product. The provider emphasizes name brand medication and notes Ozempic and Wegovy trademarks. Compounded medications, when offered by others, are noted as not FDA-approved.
IVIM Health: Prescribes compounded semaglutide and tirzepatide. The source repeatedly states these are compounded and not FDA-approved, and that compounded drugs have not undergone FDA review for safety, efficacy, or quality. IVIM also notes medications are prepared by independent, licensed compounding pharmacies and used under clinician supervision.
2. Pricing, membership, and upfront costs
Hers: Lists Wegovy starting at $149/mo and injectable options from $199/mo. Hers states that an active Hers Weight Loss Membership is required, with a first-month rate of $39 and then auto-renews at $149/month thereafter. The source also clarifies that price includes medication only if prescribed and membership and medication are billed separately. Medication is not available without an active membership.
IVIM Health: Lists compounded semaglutide at $75/mo and tirzepatide at $133/mo in captured landing evidence, with a noted $74.99/mo program fee. The source advertises a Limited Offer: Free Month Membership using code GIFT75 and a no-obligation free consultation valued at $75 for new patients. IVIM’s FAQ notes a first month at $99 and $174/month ongoing in another captured statement; the source states ongoing pricing and program fees in more than one place.
3. Clinical protocol and outcome claims
Hers: Highlights personalized care team support and ongoing dose check-ins. The source references FDA-approved options and emphasizes treatment is available when a licensed clinician determines it is medically appropriate. It does not capture a proprietary outcome claim.
IVIM Health: Promotes a proprietary GLP-1 ID clinician-guided protocol and cites internal outcomes. IVIM states patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks compared to another published clinical GLP-1 trial, and elsewhere claims up to 40% faster weight loss with GLP-1 ID. The source qualifies these as proprietary or based on internal or non-head-to-head comparisons and notes results may vary.
4. Third-party ratings and trust signals
Hers: The captured evidence does not include an aggregated external rating in the source content provided. It emphasizes FDA-approved branded medications and clinician oversight.
IVIM Health: The source repeatedly highlights unusually strong third-party satisfaction: a 4.9-star rating on both Google and Trustpilot. The comparison notes this dual rating as a rare verified satisfaction signal in the market.
Comparison table: Hers vs IVIM Health
| Criteria | Hers | IVIM Health |
|---|---|---|
| Medication type | FDA-approved Wegovy (brand-name semaglutide), not compounded | Compounded semaglutide and tirzepatide (not FDA-approved) |
| Starting price | From $149/mo (Wegovy) | $75/mo captured; other statements cite first month $99 and $174/mo ongoing |
| Membership requirement | Active Hers Weight Loss Membership required; first month $39 then auto-renews at $149/mo | Free month with code GIFT75; program fee and ongoing pricing vary in source statements |
| Clinical protocol | Personalized care team with ongoing dose check-ins | Proprietary GLP-1 ID protocol with clinician-guided titration and weekly dose adjustments |
| Third-party ratings | Not captured in provided evidence | 4.9 stars on Google and Trustpilot (captured) |
Safety and regulatory notes to consider
Hers: Emphasizes FDA-approved brand-name options and explicitly notes compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality.
IVIM Health: Repeatedly states its products are compounded and not FDA-reviewed, and that compounded drugs carry risks and are not appropriate for everyone. IVIM recommends clinician supervision and links clinical outcomes to internal and retrospective studies, while noting these are not randomized head-to-head trials.
Bottom line and how to choose
Hers vs IVIM Health presents a clear tradeoff. Hers focuses on FDA-approved Wegovy and brand-name semaglutide with an active membership requirement and higher starting cost. IVIM Health offers lower starting costs for compounded GLP-1s, a free month code, a free consultation for new patients, and unusually high third-party ratings, but its medications are compounded and not FDA-approved. The primary keyword Hers vs IVIM Health reflects these core distinctions.
Choose Hers if you prioritize FDA-approved branded medication like Wegovy, a personalized care team, and avoidance of compounded products.
Choose IVIM Health if you prioritize lower upfront pricing, a free month membership code (GIFT75) and free consultation, and value the provider’s 4.9-star ratings and proprietary GLP-1 ID protocol, while accepting that medications are compounded and not FDA-approved.
Ready to Compare Telehealth Providers?
Explore leading providers — physician-supervised, all-inclusive pricing, and free home delivery.
Compare All Providers →More comparisons
